BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Rated “Hold” by Wall Street Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been assigned an average recommendation of “Hold” from the eleven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $19.44.

Several analysts have recently weighed in on BCRX shares. Wall Street Zen lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 29th. Weiss Ratings lowered BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Wedbush cut their target price on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX traded down $0.23 during mid-day trading on Friday, hitting $7.79. The company had a trading volume of 4,399,152 shares, compared to its average volume of 5,299,524. BioCryst Pharmaceuticals has a 12 month low of $6.23 and a 12 month high of $11.22. The firm has a market cap of $1.99 billion, a P/E ratio of -5.19 and a beta of 0.55. The business’s 50-day simple moving average is $9.01 and its 200-day simple moving average is $9.15.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.15. The firm had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%. The company’s quarterly revenue was up 33.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.15 earnings per share. As a group, sell-side analysts predict that BioCryst Pharmaceuticals will post -2.28 EPS for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of BCRX. BlackRock Inc. bought a new stake in BioCryst Pharmaceuticals in the second quarter valued at about $238,930,000. Jupiter Topco LLC bought a new position in BioCryst Pharmaceuticals during the second quarter worth about $95,268,000. Janus Henderson Group PLC lifted its stake in BioCryst Pharmaceuticals by 20.3% during the first quarter. Janus Henderson Group PLC now owns 8,908,506 shares of the biotechnology company’s stock worth $84,854,000 after purchasing an additional 1,504,120 shares during the period. Perceptive Advisors LLC boosted its holdings in BioCryst Pharmaceuticals by 135.1% during the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock valued at $70,772,000 after purchasing an additional 4,271,504 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of BioCryst Pharmaceuticals by 231.6% in the 1st quarter. Bank of America Corp DE now owns 5,091,765 shares of the biotechnology company’s stock worth $48,474,000 after buying an additional 3,556,208 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes oral medicines for rare diseases. The company focuses on small-molecule therapies designed to address diseases with significant unmet medical needs, including hereditary angioedema and complement-mediated disorders.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral plasma kallikrein inhibitor used to prevent attacks of hereditary angioedema in adults and pediatric patients.